LEIDEN, NETHERLANDS--(Marketwire - January 05, 2012) - OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO) announces today that it has won an expansion of
its drug delivery technology evaluation contract
with an existing client, a top-5 global pharmaceutical company.
performed feasibility work for previous compounds of this client in
2010 and those studies have been successful. Pre-clinical studies performed
the prototype controlled release formulation were also successful.
Under the contract announced today, we will develop a controlled
formulation that combines the client's optimized product candidate
proprietary drug delivery technology PolyActive(®). If the
successful, the contract may progress to a full process
manufacturing contract, and a licensing agreement.
OctoPlus is a specialty pharmaceutical company focused on the
manufacture of improved injectable pharmaceuticals based on our proprietary
delivery technologies that exhibit fewer side effects, improved
convenience and a better efficacy/safety balance than existing
OctoPlus also focuses on the development of long-acting, controlled
versions of known protein therapeutics, peptides and small molecules,
The clinically most advanced product incorporating our
Locteron(®), a controlled release formulation of interferon
alpha for the
treatment of chronic hepatitis C. OctoPlus licensed Locteron
Biolex in October 2008. Locteron is being manufactured for Biolex by
and has completed Phase IIb clinical studies with superior clinical data
In addition, OctoPlus is a leading European provider of advanced
formulation and clinical scale manufacturing services to the
biotechnology industries, with a focus on difficult-to-formulate
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For
information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating
business, financial performance and results of the Company and the
which it operates. These statements are based on OctoPlus N.V.'s current
estimates and projections, as well as its expectations of external
and events. In particular the words "expect", "anticipate",
"estimate", "project", "plan", "may", "should", "would", "will",
"believe" and similar expressions are intended to identify forward-
statements. We caution investors that a number of important factors,
inherent risks and uncertainties that such statements involve, could
actual results or outcomes to differ materially from those expressed
forward-looking statements. In the event of any inconsistency between an
version and a Dutch version of this document, the English version will
over the Dutch version.
Click here for the press release in PDF format:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.